The Predictive Value of Metabolic Response to Preoperative Radiochemotherapy in Locally Advanced Rectal Cancer Measured by PET/CT

Overview

Journal Int J Colorectal Dis

Specialties Gastroenterology
General Surgery

Date 2008 Dec 4

PMID 19050900

Citations 25

Authors

Robert Rosenberg

Ken Herrmann

Ralf Gertler

Beat Kunzli

Markus Essler

Florian Lordick

Karen Becker

Tibor Schuster

Hans Geinitz

Matthias Maak

Markus Schwaiger

Jorg-Rudiger Siewert

Bernd Krause

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the value of positron emission tomography using fluorodeoxyglucose and computer tomography scan (FDG-PET/CT) for prediction of histopathological response of preoperative radiochemotherapy (RCTX) in patients with rectal carcinoma.

Methods: Thirty patients with uT3 rectal carcinoma were examined by FDG-PET/CT at baseline, 14 days after initiation, and after completion of preoperative RCTX. The FDG decreases seen with PET scanning from baseline to day 14 (early metabolic response) and after completion of therapy (late metabolic response) were compared with histopathological tumor response. One patient denied surgery after RCTX.

Results: The mean (+/-SD) reduction of tumor FDG uptake in histopathologically responding compared to non-responding tumors was -44.3% (+/-20.1%) versus -29.6% (+/-13.1%) (p = 0.085) at day 14 and -66.0% (+/-20.3%) versus -48.3% (+/-23.4%) (p = 0.040) after completion of RCTX. Best differentiation of histopathological tumor response was achieved by a cut-off value of 35% reduction of initial FDG uptake at day 14 and 57.5% after completion of therapy. Applying the cut-off values as a criterion for metabolic response, histopathological response was predicted with a sensitivity of 74% (14/19) at day 14 and 79% (15/19) after completion of therapy. The positive predictive value for early metabolic response was 82% (14/17) and for late metabolic response was 83% (15/18). Histopathological evidence of accumulated peritumoral inflammation cells was associated with a minor FDG decrease in five histopathologically responding patients, and influenced the results with negative predictive values of 58% (7/12) and 64% (7/11) at the early and late time points, respectively.

Conclusions: Metabolic response to a preoperative RCTX using FDG-PET/CT in rectal cancer patients can be correlated with histopathological response, but FDG uptake of peritumoral inflammation cells limited the results and led to false negative results.

Citing Articles

[F]FDG PET/CT volumetric biomarkers for non-invasive prediction of HER2 expression in breast cancer patients.

Elahmadawy M, Abdelhamed H, Gamal El-Din D, Eltohamy M, Ismail Hassan A, Abd El-Gaid S Asia Ocean J Nucl Med Biol. 2025; 13(1):10-20.

PMID: 39744060 PMC: 11682474. DOI: 10.22038/aojnmb.2024.79970.1563.

MRI VS. FDG-PET for diagnosis of response to neoadjuvant therapy in patients with locally advanced rectal cancer.

Gao P, Lu N, Liu W Front Oncol. 2023; 13:1031581.

PMID: 36741013 PMC: 9890074. DOI: 10.3389/fonc.2023.1031581.

Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment.

Nardone V, Boldrini L, Grassi R, Franceschini D, Morelli I, Becherini C Cancers (Basel). 2021; 13(14).

PMID: 34298803 PMC: 8303203. DOI: 10.3390/cancers13143590.

Comparison of percentage changes in quantitative diffusion parameters for assessing pathological complete response to neoadjuvant therapy in locally advanced rectal cancer: a meta-analysis.

Chen K, She H, Wu T, Hu F, Li T, Luo L Abdom Radiol (NY). 2020; 46(3):894-908.

PMID: 32975646 DOI: 10.1007/s00261-020-02770-6.

Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging.

Mainenti P, Stanzione A, Guarino S, Romeo V, Ugga L, Romano F World J Gastroenterol. 2019; 25(35):5233-5256.

PMID: 31558870 PMC: 6761241. DOI: 10.3748/wjg.v25.i35.5233.

References

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View

Becker K, Mueller J, Schulmacher C, Ott K, Fink U, Busch R . Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003; 98(7):1521-30. DOI: 10.1002/cncr.11660. View

Ott K, Fink U, Becker K, Stahl A, Dittler H, Busch R . Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003; 21(24):4604-10. DOI: 10.1200/JCO.2003.06.574. View

Wieder H, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A . PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2006; 34(6):878-83. DOI: 10.1007/s00259-006-0292-2. View

Watanabe T, Komuro Y, Kiyomatsu T, Kanazawa T, Kazama Y, Tanaka J . Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res. 2006; 66(7):3370-4. DOI: 10.1158/0008-5472.CAN-05-3834. View

Brucher B, Weber W, Bauer M, Fink U, Avril N, Stein H . Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001; 233(3):300-9. PMC: 1421244. DOI: 10.1097/00000658-200103000-00002. View

Wieder H, Rosenberg R, Lordick F, Geinitz H, Beer A, Becker K . Rectal cancer: MR imaging before neoadjuvant chemotherapy and radiation therapy for prediction of tumor-free circumferential resection margins and long-term survival. Radiology. 2007; 243(3):744-51. DOI: 10.1148/radiol.2433060421. View

Rimkus C, Friederichs J, Boulesteix A, Theisen J, Mages J, Becker K . Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol. 2008; 6(1):53-61. DOI: 10.1016/j.cgh.2007.10.022. View

Oku S, Nakagawa K, Momose T, Kumakura Y, Abe A, Watanabe T . FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med. 2002; 16(6):409-16. DOI: 10.1007/BF02990079. View

10.

Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R . Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005; 23(34):8688-96. DOI: 10.1200/JCO.2005.02.1329. View

11.

Kapiteijn E, Marijnen C, Nagtegaal I, Putter H, Steup W, Wiggers T . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001; 345(9):638-46. DOI: 10.1056/NEJMoa010580. View

12.

Weber W, Ott K, Becker K, Dittler H, Helmberger H, Avril N . Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001; 19(12):3058-65. DOI: 10.1200/JCO.2001.19.12.3058. View

13.

Guillem J, Chessin D, Cohen A, Shia J, Mazumdar M, Enker W . Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005; 241(5):829-36. PMC: 1357138. DOI: 10.1097/01.sla.0000161980.46459.96. View

14.

Bakx R, Emous M, Legemate D, Zoetmulder F, van Tienhoven G, Bemelman W . Harm and benefits of short-term pre-operative radiotherapy in patients with resectable rectal carcinomas. Eur J Surg Oncol. 2006; 32(5):520-6. DOI: 10.1016/j.ejso.2006.02.023. View

15.

Capirci C, Rampin L, Erba P, Galeotti F, Crepaldi G, Banti E . Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging. 2007; 34(10):1583-93. DOI: 10.1007/s00259-007-0426-1. View

16.

Lordick F, Ott K, Krause B, Weber W, Becker K, Stein H . PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8(9):797-805. DOI: 10.1016/S1470-2045(07)70244-9. View

17.

Kao P, Chou Y, Lai C . Diffuse FDG uptake in acute prostatitis. Clin Nucl Med. 2008; 33(4):308-10. DOI: 10.1097/RLU.0b013e3181662f8b. View

18.

Llamas-Elvira J, Rodriguez-Fernandez A, Gutierrez-Sainz J, Gomez-Rio M, Bellon-Guardia M, Ramos-Font C . Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging. 2006; 34(6):859-67. DOI: 10.1007/s00259-006-0274-4. View

19.

Capirci C, Rubello D, Chierichetti F, Crepaldi G, Fanti S, Mandoliti G . Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol. 2006; 187(2):W202-8. DOI: 10.2214/AJR.05.0902. View

20.

Bosset J, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L . Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355(11):1114-23. DOI: 10.1056/NEJMoa060829. View